Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 08-03 19:36:37时区推断·⟳ 抓取 08-03 19:37:43·⚡ 决策 08-04 09:40:15 +14h02m·84.6 天前
Curium拟以最高80亿美元现金及CVR收购Lantheus
Curium拟支付每股102.50美元现金，另有最高12.00美元/股CVR，合计最高114.50美元/股，对Lantheus股东是明确并购溢价。
📄 原文Investing.com↗ 原文
Curium to acquire Lantheus for up to $8 billion in cash
Oil falls over 4% as Trump calls off Iran strike, announces fresh talks BOSTON and BEDFORD, Mass. - Curium US Holdings…
不做 Lantheus（LNTH.US）
同一Curium收购Lantheus催化已在已处理消息库出现；且现价接近102.50美元现金对价，剩余为长周期并购套利，不重复做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 双方公布确定性合并协议，现金102.50美元/股加最高12.00美元/股CVR，总价值约80亿美元。市场反应:LNTH.US 8月3日收涨约1.56%，成交额和量比显著放大。
- 2026-08-04 00:05 UTC其它已处理消息库非一手已处理消息库已有BioCentury复盘同一Curium收购Lantheus催化，当前不重复推卡。
关键理由
- Curium拟支付每股102.50美元现金，另有最高12.00美元/股CVR，合计最高114.50美元/股，对Lantheus股东是明确并购溢价。
- 但同一Curium收购Lantheus催化已在近72小时已处理消息库中出现：2026-08-04 00:05 UTC BioCentury复盘放射性药物并购已覆盖该交易。
- Lantheus（LNTH.US）现价约101.19美元，接近102.50美元确定现金对价；CVR非转让且取决于2030年前商业里程碑，已不适合作为短线事件交易。
主要风险
- 交易仍需股东及监管批准，预计2027年上半年才关闭，剩余价差主要是并购套利而非短线催化。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-03 · 影响 weakens
反证主要是股东和监管审批、CVR里程碑不确定以及关闭周期长；不否定并购利好，但削弱短线交易edge。
检索:Curium Lantheus definitive agreement $102.50 CVR regulatory approval risks 原文 ↗ - 做多前查反向 · 来源 search_processed_events · 日期 2026-08-04 · 影响 invalidates
命中2026-08-04 00:05 UTC已处理消息：BioCentury复盘放射性药物并购包含Curium收购Lantheus。
检索:search_processed_events LNTH.US Curium Lantheus 72h
工具调用 · 历史记录,结果未知(2 种)
- stock_quote · 结果未知
- search_processed_events · 结果未知
原文全文
展开原文 · 2,404 字
Oil falls over 4% as Trump calls off Iran strike, announces fresh talks
BOSTON and BEDFORD, Mass. - Curium US Holdings LLC announced today it has entered into a definitive agreement to acquire Lantheus Holdings, Inc. (NASDAQ:LNTH) for $102.50 per share in cash at closing, plus contingent value rights providing for up to $12.00 per share in additional payments.
The total transaction consideration of up to $114.50 per share values the deal at approximately $8.0 billion. The cash consideration at closing represents a premium of 38% to Lantheus’ 60-day volume-weighted average price and 29% to its 30-day volume-weighted average price as of May 21, 2026, according to a press release statement.
The contingent value rights are tied to specified commercial milestones for Lantheus’ products through 2030. These milestones include sales targets for the company’s global prostate cancer diagnostics franchise, global neurology diagnostics, and DEFINITY business. The CVRs are non-transferable and there is no assurance any payments will be made.
Lantheus’ Board of Directors unanimously approved the transaction. The board conducted a comprehensive evaluation of strategic options, including outreach to multiple third parties and remaining standalone, before determining this transaction maximizes shareholder value.
The combined company would serve patients across more than 70 countries. Curium operates over 80 manufacturing sites globally with a portfolio of over 45 products. Lantheus has been providing radiopharmaceutical solutions for 70 years and markets products including PYLARIFY for prostate cancer imaging and DEFINITY for cardiac ultrasound.
The transaction is expected to be financed through a combination of debt and equity and is not subject to financial conditions. Lantheus will continue operating as an independent, publicly traded company until closing, which is expected in the first half of 2027.
Completion of the transaction is subject to Lantheus shareholder approval and regulatory approvals. Lantheus plans to announce second quarter 2026 financial results on August 6 and will suspend its previously issued fiscal year 2026 guidance due to the pending transaction.
Curium was established in 2017 by CapVest Partners LLP, which remains its controlling shareholder.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
BOSTON and BEDFORD, Mass. - Curium US Holdings LLC announced today it has entered into a definitive agreement to acquire Lantheus Holdings, Inc. (NASDAQ:LNTH) for $102.50 per share in cash at closing, plus contingent value rights providing for up to $12.00 per share in additional payments.
The total transaction consideration of up to $114.50 per share values the deal at approximately $8.0 billion. The cash consideration at closing represents a premium of 38% to Lantheus’ 60-day volume-weighted average price and 29% to its 30-day volume-weighted average price as of May 21, 2026, according to a press release statement.
The contingent value rights are tied to specified commercial milestones for Lantheus’ products through 2030. These milestones include sales targets for the company’s global prostate cancer diagnostics franchise, global neurology diagnostics, and DEFINITY business. The CVRs are non-transferable and there is no assurance any payments will be made.
Lantheus’ Board of Directors unanimously approved the transaction. The board conducted a comprehensive evaluation of strategic options, including outreach to multiple third parties and remaining standalone, before determining this transaction maximizes shareholder value.
The combined company would serve patients across more than 70 countries. Curium operates over 80 manufacturing sites globally with a portfolio of over 45 products. Lantheus has been providing radiopharmaceutical solutions for 70 years and markets products including PYLARIFY for prostate cancer imaging and DEFINITY for cardiac ultrasound.
The transaction is expected to be financed through a combination of debt and equity and is not subject to financial conditions. Lantheus will continue operating as an independent, publicly traded company until closing, which is expected in the first half of 2027.
Completion of the transaction is subject to Lantheus shareholder approval and regulatory approvals. Lantheus plans to announce second quarter 2026 financial results on August 6 and will suspend its previously issued fiscal year 2026 guidance due to the pending transaction.
Curium was established in 2017 by CapVest Partners LLP, which remains its controlling shareholder.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。